文獻標題： 1："kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Chapman AB1, Devuyst O2, Eckardt KU3, Gansevoort RT4, Harris T5, Horie S6, Kasiske BL7, Odland D8, Pei Y9, Perrone RD10, Pirson Y11, Schrier RW12, Torra R13, Torres VE14, Watnick T15, Wheeler DC16; Conference Participants." 2："Kidney Int. 2015 Oct;88(4):676-83. doi: 10.1038/ki.2015.28. Epub 2015 Mar 4. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. Eckardt KU1, Alper SL2, Antignac C3,4, Bleyer AJ5, Chauveau D6, Dahan K7, Deltas C8, Hosking A9, Kmoch S10, Rampoldi L11, Wiesener M1, Wolf MT12, Devuyst O13; Kidney Disease: Improving Global Outcomes." 3：alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 1 trials.the lan lancet et oncology. 4：Topical treatment of glaucoma: established and emerging pharmacology 5：Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.   [更多]

求購Rotigotine Transdermal System《USP43-NF38》的藥典標準一份   [更多]

求購Monographs: Medicinal and Pharmaceutical Substances:Rotigotine《BP2020》的藥典標準一份   [更多]

求購“Oseltamivir phosphate”《 EP9.2 》的藥典標準一份.   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

求購<71> Sterility Tests《USP43-NF38》的藥典標準一份   [更多]

求購“Ibuprofen”《 EP9.4 》的藥典標準一份，謝謝。   [更多]

求購硫酸氨基葡萄糖膠囊（商品名為：Viartril-S，維固力，持證商為：ROTTAPHARM S.P.A）產(chǎn)品特性說明   [更多]

文獻標題： 1、hyuedyhiyhfeh 備注：將符合標題的文獻PDF格式上傳，符合要求者先到先得   [更多]

求購“Lysine hydrochloride”《 EP9.4 》的藥典標準一份.   [更多]